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Abstract
Background: Sensitive diagnostic tools are necessary for the detection of Mycobacterium suricattae infection in
meerkats (Suricata suricatta) in order to more clearly understand the epidemiology of tuberculosis and the
ecological consequences of the disease in this species. We therefore aimed to develop a cytokine release assay to
measure antigen-specific cell-mediated immune responses of meerkats.
Results: Enzyme-linked immunosorbent assays (ELISAs) were evaluated for the detection of interferon-gamma
(IFN-γ) and IFN-γ inducible protein 10 (IP-10) in meerkat plasma. An IP-10 ELISA was selected to measure the release
of this cytokine in whole blood in response to Bovigam® PC-HP Stimulating Antigen, a commercial peptide pool of
M. bovis antigens. Using this protocol, captive meerkats with no known M. suricattae exposure (n = 10) were tested
and results were used to define a diagnostic cut off value (mean plus 2 standard deviations). This IP-10 release
assay (IPRA) was then evaluated in free-living meerkats with known M. suricattae exposure, categorized as having
either a low, moderate or high risk of infection with this pathogen. In each category, respectively, 24.7%, 27.3% and
82.4% of animals tested IPRA-positive. The odds of an animal testing positive was 14.0 times greater for animals
with a high risk of M. suricattae infection compared to animals with a low risk.
Conclusion: These results support the use of this assay as a measure of M. suricattae exposure in meerkat
populations. Ongoing longitudinal studies aim to evaluate the value of the IPRA as a diagnostic test of M. suricattae
infection in individual animals.
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Background
In the Kalahari Desert of South Africa, tuberculosis (TB)
caused by Mycobacterium suricattae results in morbidity
and mortality in meerkats [1, 2]. In this species, TB
presents as disseminated disease primarily affecting the
spleen, liver, lungs and head lymph nodes and a charac-
teristic clinical finding is swelling of the sub-mandibular
lymph nodes [1] (Fig. 1). Clinical disease often pro-
gresses to mortality resulting in changes in population
ecology through group-level extinctions [3].
Improved diagnostic tests for TB in meerkats are
necessary to advance the understanding of disease
epidemiology and may allow the development of an
effective TB control strategy. Serological assays for TB
have previously been shown to have low sensitivity in
this species [4]; however, assays detecting cell-mediated
immune responses have, to date, not been evaluated [5].
In other species, such as cattle, in vitro tests of cell-
mediated immunity (CMI) offer the most sensitive
methods for TB diagnosis by detecting the release of
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interferon-gamma (IFN-γ) in response to mycobacterial
antigens [6, 7]. Moreover, an alternative diagnostic marker
of CMI, IFN-γ-inducible protein 10 (IP-10), has been
shown to improve diagnostic sensitivity in humans and
buffaloes (Syncerus caffer) [8, 9]. The specificity of such as-
says can be optimised by using highly specific antigens
such as 6 kDa early secretory antigenic target (ESAT-6)
and 10 kDa culture filtrate protein (CFP-10) [10, 11].
However, the genes encoding these proteins have been
deleted from M. suricattae and they are therefore unlikely
to be suitable diagnostic antigens for this pathogen [2]. As
an alternative, the commercially available Bovigam® PC-
HP peptide pool, which contains ESAT-6 and CFP-10
peptides, includes antigens derived from the gene Rv3615c
and an additional 3 genes, and could be useful for the
detection of M. suricattae infection [11].
The purposes of this study were, therefore, to develop
enzyme-linked immunosorbent assays (ELISAs) for the
measurement of IFN-γ and IP-10 in meerkat plasma,
evaluate the diagnostic utility of the PC-HP peptide pool
in this species, and assess the test performance of an
optimised diagnostic assay for M. suricattae infection in
a population of free-living meerkats.
Materials and methods
Animals
Captive meerkats with no known history of M. suricat-
tae exposure served as an uninfected control group for
the development of the cytokine release assay. These
animals (n = 10) were housed in two groups on a natural
soil substrate in an enriched environment in enclosures
(6 × 10 meters) at Giraffe House, a wildlife awareness
centre situated in Stellenbosch, South Africa. They were
fed eggs and day-old chicks or chicken meat daily and
had free access to clean water.
Animals with known exposure to M. suricattae were
opportunistically sampled from a population of free-living
meerkats, which have been habituated to the presence
of researchers [12], from the Kuruman River Reserve,
Northern Cape, South Africa (26°58’S, 21°49’E). Between
September 2014 and February 2015, animals from this
population were sampled from 12 social groups. Hereafter,
animals were classified according to their presumed infec-
tion risk: low risk (category 1), comprising animals from
social groups with no known history of TB; intermediate
risk (category 2), comprising animals from social groups
with either one or two known deaths due to TB in the
preceding two years; and high risk (category 3), compris-
ing meerkats from social groups with more than two
deaths due to TB in the preceding two years.
Permission to perform the study was obtained from
the University of Stellenbosch Animal Ethics committee
(Reference no. SU-ACUM14-00042). Permits to conduct
animal research were obtained from the Northern Cape
Department of Environment and Nature Conservation
(Permit no. FAUNA 194/2014) and the National Depart-
ment of Agriculture, Forestry and Fisheries (Reference
no. 12/11/1/7/3).
Blood collection and processing
Meerkats were captured by hand and placed in cotton bags
or caught in nets and physically restrained with towels prior
to induction and maintenance of anaesthesia with isoflur-
ane (Safeline Pharmaceuticals Ltd, Roodepoort, SA) via
facemask. Using a 25G needle and syringe, 2 ml blood was
collected from the jugular vein and transferred to a hepari-
nised blood tube (Greiner Bio-one, Kremsmünster, Austria).
Animals were monitored after completion of the pro-
cedure and returned to their natural environment once
fully recovered.
Fig. 1 Meerkats with pathology typical of tuberculosis caused by Mycobacterium suricattae. a A meerkat displaying swelling of the submandibular
lymph node. These lesions typically present at post mortem as granulomatous hyperplasia. b A meerkat with a draining sinus tract following
necrosis and abscessation of the submandibular lymph node
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Aliquots of whole blood (150 μl) were transferred to each
of three 1.5 ml microcentrifuge tubes containing, respect-
ively, 15 μl phosphate buffered saline (PBS); 15 μl PC-HP
peptide solution (Prionics AG, Schlieren, Switzerland),
prepared according to the manufacturer’s instructions; and
15 μl pokeweed mitogen (PWM) solution in PBS (final
concentration 50 μg/ml). Tubes were thoroughly mixed,
incubated at 37 °C for 24 hours and centrifuged at 1300 × g
for 6 minutes, after which the plasma was harvested and
stored at - 80 °C.
ELISA protocol
All ELISAs described below were performed according
to the following protocol. Capture antibody (Table 1) in
PBS (50 μl) was used to coat wells of 96-well MaxiSorp
polystyrene ELISA plates (Thermo Fisher Scientific,
Massachusetts, USA) which were incubated at 4 °C
overnight. All subsequent steps were performed at room
temperature. Plates were washed three times with wash
buffer (WB) consisting of 0.05% Tween-20 (Sigma-Aldrich,
Missouri, USA) in PBS and blocked with 200 μl/well block-
ing buffer (BB) comprising WB with 0.1% bovine serum
albumin (Roche, Basel, Switzerland). After 1 h incubation,
plates were washed again. For IFN-ɣ assays, 25 μl of
each plasma sample was incubated with 25 μl BB and
for IP-10 assays, 12.5 μl of each plasma sample with
37.5 μl BB. After 2 h, plates were washed and incu-
bated for 1 h with 50 μl/well biotinylated detection
antibody (Table 1) diluted in BB. After washing, plates
were incubated for an additional 1 h with 50 μl/well
streptavidin-horseradish peroxidase (R&D systems,
Minnesota, USA) diluted 1:200 in BB. After a final
wash step, plates were incubated for 20 minutes with
50 μl/well tetramethylbenzidine (TMB) substrate solu-
tion (BD Pharmingen, New Jersey, USA) after which
sulphuric acid (2 M; 25 μl/well) was added to stop the
colour reaction. The optical density (OD) of each well
was measured at 450 nm using an LT-4000 Microplate
Reader (Labtech, Uckfield, UK).
Antibody selection and ELISA optimisation
Selected anti-IFN-ɣ and anti-IP-10 antibodies (Table 1)
were screened for potential reactivity to these cytokines in
meerkat plasma as follows. Plasma from PWM-stimulated
blood of 7 randomly selected animals was pooled and
assayed using ELISAs comprising all possible combinations
of selected capture and detection antibodies for either IFN-
ɣ or IP-10. All antibodies were used at concentrations rec-
ommended by the manufacturer (Table 1). The antibody
combination that resulted in the greatest OD values for
each analyte was then selected and a dilution series of these
antibodies was used in a checkerboard titration to assay
pooled plasma samples from both PWM-stimulated and
unstimulated blood. The optimal ELISA conditions were
defined as the concentrations of capture and detection anti-
bodies which resulted in the greatest relative OD difference
derived from these samples.
Cytokine release assay
Plasma samples, derived from whole blood which was
processed as described above, were assayed in duplicate
using the optimised ELISA. M. suricattae-specific cytokine
release was defined as the OD obtained for the PC-HP-
stimulated sample minus that for the sample co-incubated
with PBS (ODHP-Nil). The PWM-stimulated plasma
sample was used as a positive control for whole blood
cytokine release and animals that showed greater cyto-
kine release in whole blood co-incubated with PBS than
in response to PWM stimulation (ODPWM-nil < 0) were
excluded from the study. Using the results from unin-
fected control animals, a diagnostic cut off value for
this assay was calculated as the mean of all ODHP-Nil
values plus 2 standard deviations (SD).
Statistical analysis
Using the Wilcoxon signed rank test, the release of IP-
10 in blood co-incubated with PBS, PC-HP and PWM
was compared for animals from the uninfected control
group as well as those from the M. suricattae-exposed
Table 1 Capture and detection antibodies screened for use in enzyme-linked immunosorbent assays for the detection of meerkat
interferon-gamma (IFN-ɣ) and IFN-γ inducible protein 10 (IP-10)
Cytokine Species Manufacturer Antibody catalogue no.
Capture Detection
IFN-ɣ Human BD Pharmingen, New Jersey, USA 551221 554550
Equine Mabtech, Nacka Strand, Sweden 3117-1H-6 3117-1H-6
Feline R&D Systems Minnesota, USA DY764 DY764
Feline AbD Serotech, Kidlington, UK MCA2140 N/A
Feline Kingfisher Biotech, Minnesota, USA PB0281F-100 PBB0283F-050
IP-10 Human Peprotech, London, UK 900-K39 500-P93Bt
Equine Kingfisher biotech PB0418E-100 PBB0423E-050
Bovine Kingfisher biotech PB0385B-100 PBB0393B-050
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group. Data were analysed using GraphPad Prism 5
(GraphPad Software, Inc., La Jolla, USA). The perform-
ance of the cytokine release assay was evaluated in the
free-living M. suricattae-exposed meerkat population by
calculating the odds of an animal testing positive in each
of the three infection risk categories defined above.
These values were compared to that of category 1 using
a chi-squared analysis.
Results
Development of a meerkat cytokine release assay
Of the ELISAs evaluated for the detection of meerkat
IFN-γ (Table 1), the assay comprising anti-human cap-
ture (2 μg/ml) and detection (2 μg/ml) antibodies
resulted in the greatest OD value for PWM-stimulated
samples, i.e. OD = 0.076. Of the IP-10 ELISAs (Table 1),
the assay consisting of anti-bovine capture antibody
(0.5 μg/ml) and anti-human detection antibody (0.25 μg/
ml) resulted in the greatest ELISA signal, i.e. OD = 0.45.
Hereafter, the IP-10 assay was selected for further
analysis of PC-HP-stimulations and recombinant human
IP-10 protein (Peprotech) was used as a positive control
for the assay. Meerkats in the uninfected control group
showed no significant difference in IP-10 release in
blood incubated with PC-HP peptides and blood co-
incubated with PBS (Fig. 2a). However, there was a sig-
nificant difference in the release of this cytokine in
PWM-stimulated blood and blood co-incubated with
PBS (Fig. 2a). Using the IP-10 release assay (IPRA) test
results (ODHP-Nil) from this group, a diagnostic cut off
value was calculated as 0.038 (mean ODHP-Nil + 2SD).
This value was then used to classify meerkats from the
low, intermediate and high infection risk categories as
either IPRA-positive or -negative.
Evaluation of test performance
A total of 108M. suricattae-exposed meerkats were
tested: 79 from social groups with no known history of
TB (category 1), 11 from social groups with one or two
deaths due to TB (category 2), and 18 from social groups
with 3 to 7 deaths (category 3). For these animals, the
ODHP (median 0.20, interquartile range 0.16–0.32), and
the ODPWM (0.50, 0.32–0.69), were both significantly
greater than the ODNil (0.19, 0.15–0.27) (Fig. 2b). The
median ODPWM-Nil value was 0.29 (range,−0.36 to 0.84)
and 6/79, 0/11 and 1/18 animals from categories 1, 2
and 3, respectively, were excluded from further analysis
on the basis of their ODPWM-Nil result being less than
zero. Of these 7 cases, 5 had ODNil values in the highest
quartile of all samples.
For the remaining 101 meerkats, 35 animals had values
greater than the diagnostic cut off (ODHP-Nil > 0.038)
(Table 2) with 24.7% testing positive in category 1, 27.3%
in category 2 and 82.4% in category 3. The odds of an
animal testing IPRA-positive was 14.0 times greater for
animals with a high risk of M. suricattae infection
(category 3) compared to animals with a low risk
(category 1) (95% CI: 3.6–54.3, p < 0.0001).
Discussion
We have developed a novel diagnostic assay for M.
suricattae infection in meerkats which measures antigen-
specific IP-10 release in whole blood incubated with
Bovigam® PC-HP peptides. All meerkats with no known
exposure to M. suricattae (n = 10) tested negative with
the IPRA, while 35 out of 101 (34.6%) animals with
known exposure to this pathogen tested positive. Al-
though M. suricattae infection in these individuals was
not confirmed, the odds of a meerkat testing positive
were significantly greater for animals with a high risk of
infection when compared to those with a low risk of
infection, supporting the validity of the IPRA.
IP-10 has been shown to be a useful diagnostic bio-
marker for detection of M. tuberculosis infection in
humans [9] and M. bovis infection in African buffaloes
[11]. In both these species, IP-10 is produced in greater
Fig. 2 IP-10 release in whole blood incubated at 37 °C for 24 h with phosphate buffered saline (Nil), Bovigam PC-HP peptides and pokeweed
mitogen (PWM), from a Mycobacterium suricattae-unexposed meerkats (n = 10), and b M. suricattae-exposed meerkats (n = 101). Significant
differences between treatment conditions are indicated (Wilcoxon signed rank test, *p < 0.005)
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amounts than IFN-γ in antigen-stimulated whole blood
and has been shown to be a more sensitive marker of
mycobacterial infection [8, 9, 13]. In the present study,
despite the use of ELISA antibodies produced against
distantly related species, measurement of IP-10 proved
to be a useful marker of immune activation. While this
indicates the sensitivity of the ELISA for meerkat IP-10,
it may, in part, reflect the abundance of this molecule in
antigen-stimulated samples. Moreover, the similarity
between the amino acid sequences of cattle, horses, cats
and humans is significantly greater for IP-10 than for
IFN-γ (data not shown) and this may explain the
increased potential for cross-species reactivity of the
anti-IP-10 antibodies. For these reasons, IP-10 may also
be a useful diagnostic target in other species.
In order to define a diagnostic cut off value for the
IPRA, we tested 10 captive meerkats with no known
exposure to M. suricattae. These animals showed no
significant difference in their IP-10 responses to PBS
and PC-HP peptides indicating that their selection as
uninfected controls was appropriate. Moreover, a thresh-
old value of ODHP-Nil > 0.038 classified all control ani-
mals as test-negative. Such a low threshold will increase
the sensitivity of the assay, thereby reducing the num-
ber of false negative test results; however, this could
be at the expense of specificity [14]. In part, this low
cut off value resulted from plasma samples being di-
luted 1:4 in the present study and a lower dilution
factor might improve test accuracy. However, this was
not tested in the present study because of limited
sample volumes.
In contrast to the control animals, 35 of 101M. suri-
cattae-exposed meerkats displayed significant IP-10
responses to the PC-HP peptides, confirming the anti-
genicity of this peptide pool for these animals. How-
ever, it is currently unclear which components of the
PC-HP antigens might be responsible for this immune
sensitization. The genetic region of difference 1 (RD1), a
variant of which is deleted from the M. suricattae genome
[15], encodes both ESAT-6 and CFP-10 and is also re-
quired for the secretion of Esx-1 substrate protein C
(espC) which is encoded by the gene Rv3615c [16].
While Rv3615c is present in the M. suricattae gen-
ome (pers. comm., Anzaan Dippenaar), it is possible
that this component of the PC-HP peptide pool, in
addition to ESAT-6/CFP-10, would have a limited
diagnostic contribution to detection of M. suricattae-
infected animals. Nonetheless, the use of the PC-HP
reagent is supported by the fact that the odds of an
animal testing IPRA-positive were significantly greater
for meerkats with the greatest risk of M. suricattae
infection. Moreover, our results suggest that the PC-
HP peptides might be useful for diagnostic testing of
species infected with related RD1-deleted strains, i.e.
M. microti, M. mungi and the dassie bacillus [5].
In both the captive and free-living populations, the
median ODPWM was significantly higher than the values
for either ODNil or ODHP, indicating that PWM is an
appropriate mitogen in this species. Seven animals were
excluded from our analysis based on negative ODPWM-Nil
values; however, in 5 of these cases, the exclusion criterion
was met as a result of unusually high ODNil values, not
failure to respond to PWM. Similar spontaneous release
of IP-10 has previously been seen in cattle [17],
although the mechanism for this phenomenon is not
currently understood. In the present study, although
the positive control was intended to confirm the
viability of cytokine production in blood samples, it
additionally served to identify samples where high
ODNil values would have affected the test interpret-
ation. In such cases, repeat sampling of the animal
would be recommended.
Conclusion
The measurement of PC-HP induced IP-10 release is
a useful biomarker of the risk of M. suricattae infec-
tion in meerkat populations. Moreover, while no M.
suricattae-unexposed meerkats tested IPRA-positive,
numerous animals from the exposed population with
known cases of TB did, suggesting that the assay
shows promise as a specific test for individual ani-
mals. Ongoing work which includes longitudinal test-
ing and confirmation of infection status seeks to
confirm the assay’s utility in individual meerkats. This
IPRA will have use in further clarifying the epidemi-
ology of M. suricattae infection in meerkats and test
results may be used to inform management strategies
for infected populations.
Table 2 Analysis of IP-10 release assay (IPRA) results for 101 opportunistically sampled meerkats with a low, intermediate and high
risk of infection with M. suricattae
Category Infection risk (n) Positive (%) ORa (95% confidence interval) P
1 Low (73) 18 (24.7) 1 -
2 Medium (11) 3 (27.3) 1.13 (0.27–4.70) 0.87
3 High (17) 14 (82.4) 14 (3.61–54.34) <0.0001
Total 101 35 (34.7)
aOR, Odds ratio of an animal in a particular category testing positive, relative to category 1
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Additional file
Additional file 1: IP-10 release in whole blood from Mycobacterium
suricattae-unexposed meerkats (Control Group) and meerkats with a low
risk (Category 1), moderate risk (Category 2) and high risk (Category 3) of
infection with this pathogen. Blood was incubated at 37 °C for 24 h with
phosphate buffered saline (Nil), Bovigam PC-HP peptides (HP) and
pokeweed mitogen (PWM). The HP-specific (HP-Nil) and PWM-specific
(PWM-Nil) IP-10 release was calculated by subtracting the Nil value from
the HP and PWM values, respectively. (XLSX 21 kb)
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